Related Experiment Video

Updated: Aug 22, 2026

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
10:59

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment

Published on: November 23, 2017

Plasminogen activator inhibitor-1

Ann Gils1, Paul J Declerck

  • 1Laboratory for Pharmaceutical Biology and Phytopharmacology, Katholieke Universsiteit Leuven, Van Evenstraat 4, B-3000 Leuven, Belgium. ann.gils@pharm.kuleuven.ac.be

Current Medicinal Chemistry
|September 24, 2004
PubMed

Insights

Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of the plasmin system, impacting cardiovascular health and tumor growth. This review covers PAI-1

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue-type (t-PA) and urokinase-type (u-PA) plasminogen activators.
  • PAI-1 is crucial in regulating fibrinolysis and has significant roles in cardiovascular diseases, cell migration, and tumor progression.
  • As a member of the serpin superfamily, PAI-1 possesses unique structural and functional characteristics.

Purpose of the Study:

  • To provide a comprehensive overview of PAI-1 knowledge accumulated over two decades.
  • To discuss the structure-function relationships of PAI-1.
  • To explore strategies for pharmacological modulation of PAI-1 as a therapeutic target.

Main Methods:

  • Literature review and synthesis of existing research on PAI-1.
  • Analysis of PAI-1's structural and conformational properties.
  • Examination of PAI-1's involvement in various physiological and pathological processes.

Main Results:

  • PAI-1's unique structural features dictate its inhibitory functions.
  • PAI-1 significantly influences cardiovascular homeostasis and tumorigenesis through t-PA and u-PA inhibition.
  • Diverse strategies exist to modulate PAI-1 activity for therapeutic benefit.

Conclusions:

  • PAI-1 is a multifaceted protein with critical roles in health and disease.
  • Understanding PAI-1's structure-function dynamics is essential for developing targeted therapies.
  • Pharmacological targeting of PAI-1 holds promise for managing cardiovascular diseases and cancer.

More Related Videos

Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus06:45

Affinity Purification of a Fibrinolytic Enzyme from Sipunculus nudus

Published on: June 2, 2023

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well08:01

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...